Cardiorenal interactions in heart failure: insights from recent therapeutic advances.
| Autor: | Damman K; University of Groningen, Department of Cardiology, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands., Testani J; Yale University School of Medicine, Section of Cardiovascular medicine, Yale University, New Haven, CT, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiovascular research [Cardiovasc Res] 2024 Oct 14; Vol. 120 (12), pp. 1372-1384. |
| DOI: | 10.1093/cvr/cvad096 |
| Abstrakt: | Heart failure is a syndrome that may develop when cardiovascular disease progresses or is insufficiently treated and associated with a poor quality of life, high mortality rates, and increased healthcare expenditures. Prevention and treatment of heart failure are therefore of utmost importance. New therapies in patients with cardiovascular disease have recently been shown to be effective in the prevention and sometimes treatment of heart failure, and additional research is underway. Specifically, in high-risk patients with either (a combination of) diabetes, chronic kidney disease, and/or heart failure, three specific drug classes [sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1-RAs), and non-steroidal mineralocorticoid receptor antagonists (MRAs)] have taken centre stage in therapeutic approach for these high cardiovascular risk patients. The commonality of these drugs is the finding that they improve cardiovascular and renal endpoints across the cardiorenal continuum and SGTL2i have already proved effective in all subtypes of heart failure, while we await data on non-steroidal MRA therapy in heart failure. The story may be different for GLP-1-RA in patients with established heart failure, but these drugs are effective in reducing cardiovascular events in patients with diabetes. Taken together, these new therapies advance the treatment and improve the associated outcomes of patients with cardiorenal disease and diabetes, with similar characteristics and effectiveness in different conditions. Competing Interests: Conflict of interest: KD reports speaker/consultancy fees to his employer by AstraZeneca, Boehringer Ingelheim, Abbott, Novartis, FIRE1. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|